Bank of Montreal Can Sells 1,881 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Bank of Montreal Can lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 32.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,993 shares of the company's stock after selling 1,881 shares during the quarter. Bank of Montreal Can's holdings in Medpace were worth $1,327,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Medpace during the 4th quarter valued at about $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace in the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp grew its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

MEDP stock traded up $10.94 on Wednesday, reaching $293.22. The company's stock had a trading volume of 276,629 shares, compared to its average volume of 335,622. The firm has a market cap of $8.86 billion, a PE ratio of 23.22, a PEG ratio of 3.81 and a beta of 1.46. The business has a fifty day simple moving average of $316.36 and a two-hundred day simple moving average of $332.53. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The firm had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same period last year, the company posted $3.20 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Robert W. Baird reduced their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday. Mizuho reduced their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. William Blair reissued a "market perform" rating on shares of Medpace in a research note on Tuesday. Truist Financial reduced their price target on Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Finally, Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $352.60.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.